Bicalutamide competitively blocks the binding of androgen receptors in target tissues, resulting in growth arrest or transient tumour regression through inhibition of androgen-dependent DNA and protein synthesis.
Bicalutamide competitively blocks the binding of androgen receptors in target tissues, resulting in growth arrest or transient tumour regression through inhibition of androgen-dependent DNA and protein synthesis.
